Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment
PROTAC, Antibodies, CGT, AI/Digital Technology All Eyed
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
You may also be interested in...
Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
New Funding Nectar For Hummingbird As It Progresses Novel Antibodies
Singapore- and US-based rational antibody design venture closes major new financing to support progress of its novel pipeline, with its two lead assets set to enter the clinic shortly. CEO Piers Ingram talks to Scrip about plans and strategy.
Yposkesi Acquisition Fuels SK's Global Push Into Biologics Manufacturing
South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.